• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Jun17
FactSet Analysts Rate Blueprint Medicines as Hold
11:46
Jun12
Blueprint Medicines Presents Long-Term Efficacy and Safety Data for AYVAKIT in Systemic Mastocytosis
22:01
Jun2
Blueprint Medicines Rated as Outperform
15:52
May1
Blueprint Med released FY2025 Q1 earnings on May 1 During-Market EST, actual revenue USD 149.41 M (forecast USD 156.89 M), actual EPS USD 0.0077 (forecast USD -0.4585)
20:00
Apr24
Blueprint Med to release FY2025 Q1 earnings report on May 1 During-Market EST, forecast revenue USD 157.25 M, EPS USD -0.4514
00:05
Feb13
Blueprint Med released FY2024 Q4 earnings on February 13 During-Market (EST), actual revenue $146.37M (forecast $145.18M), actual EPS -$0.7854 (forecast -$0.7095)
21:00

Schedules & Filings

Schedules
Filings
May1
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 149.41 M, Net Income 496 K, EPS 0.0077

Feb13
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 146.37 M, Net Income -49.96 M, EPS -0.7854

Oct30
Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 128.18 M, Net Income -56.28 M, EPS -0.8879

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More